Recently, glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) have received much attention regarding possible roles in aetiology and treatment of type 2 diabetes. However, peptides co-secreted from the same enteroendocrine cells are less well studied. The present investigation was designed to characterise the in vitro and in vivo effects of xenin, a peptide co-secreted with GIP from intestinal K-cells. We examined the enzymatic stability, insulin-releasing activity and associated cAMP production capability of xenin in vitro. In addition, the effects of xenin on satiety, glucose homoeostasis and insulin secretion were examined in vivo.
- xenin peptide
- insulin secretion
- type 2 diabetes
- glucose homoeostasis
Taylor, A., Irwin, N., McKillop, A., Patterson, S., Flatt, P., & Gault, V. (2010). Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety. Journal of Endocrinology, 207(1), 87-93. https://doi.org/10.1677/JOE-10-0085